Myrelez (Lanreotide Acetate)

Lanreotide acetate mimics natural somatostatin and binds to somatostatin receptors, especially SSTR2 and SSTR5. This binding blocks adenylate cyclase, lowers cyclic AMP, and suppresses the release of growth hormone and other peptide hormones that drive tumor growth and metabolic disturbances.

The specific dose and dosing interval of Myrelez are determined by the prescribing clinician based on the individual’s disease severity, response to therapy, and other clinical factors. Patients should follow the prescriber’s instructions and not alter the regimen without medical advice.

Safety data for lanreotide acetate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Myrelez product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Myrelez is a long‑acting somatostatin analogue similar to octreotide but offers a longer dosing interval, often every 4‑8 weeks, which can improve convenience. Compared with pegvisomant, a growth‑hormone receptor antagonist, lanreotide works by suppressing hormone secretion rather than blocking its action, and the choice depends on patient response, tolerance and physician preference.

Myrelez should be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 24 hours and return to refrigeration promptly.

Myrelez is given by subcutaneous injection, typically performed by a healthcare professional. The injection is administered into the abdomen or thigh using a pre‑filled syringe or autoinjector, following aseptic technique and the dosing schedule prescribed by the treating physician.

Serious adverse events include gallbladder disease (such as cholelithiasis), acute pancreatitis, severe hyperglycaemia that may require medical intervention, and rare but potentially life‑threatening allergic reactions. Patients should be monitored regularly for these conditions and instructed to report any concerning symptoms promptly.

Myrelez is contraindicated in patients with known hypersensitivity to lanreotide acetate or any of the formulation excipients. Caution is advised for individuals with severe uncontrolled diabetes, active gallbladder disease, or those who are pregnant or breastfeeding unless the benefits outweigh the risks.